


Welcome to the second NCPV newsletter—Happy New Year!



NCPV's global impact in 2016: Zika virus and beyond

During 2016 NCPV was at the forefront of the global response to the outbreak of Zika virus that has affected people in up to 70 countries across South America, the Caribbean and the Western Pacific Region since October 2013. We supplied live Zika virus strains or RNA from NCPV Zika strains to 50 different groups of scientists in 16 countries. NCPV also made publically available the first Zika virus strain with extensive genome sequence data isolated from a semen sample.

In addition, NCPV viruses were cited in more than 10 peer-reviewed publications from around the globe. Read more about the varied research being undertaken and the potential impact on global public health.

[Read more](#)

**Looking for a Certificate of Analysis (CoA) for a virus you have recently purchased?
All CoAs are now available online.**

Yellow Fever - a persisting pathogen

Yellow fever virus is an arbovirus of the Flaviviridae family, pathogenic to humans, and transmitted by mosquitoes (*Aedes* and *Haemagogus* species). It is endemic in tropical areas of Africa and South America and although vaccination is available, take-up is low in some endemic areas. In 2015/2016 a large outbreak occurred in Angola and the Democratic Republic of Congo, and in Brazil this year, 47 cases have been confirmed and there have been 25 deaths.





[Find out more](#)

Why deposit strains with NCPV?

There are many benefits of depositing your strains with NCPV. It is free of charge to deposit and you will have access your deposited strains at any time and without charge.

The process for depositing is straightforward and international dispatch, including biosecurity and licence requirements, is managed for you.

NCPV will independently authenticate the identity and sterility of your strains and you retain Intellectual Property Rights on all material.



An added advantage is that it makes it easier to fulfil your obligation to make strains available after publication.

Your viruses can be made available through flexible release dates. For example, you can request a virus to be distributed only after you have published your paper helping to raise the profile of your peer-reviewed publications by requiring other users to cite original work.

The research community will then be able to reproduce and build on your work more readily and your work will continue to be available to future generations of researchers.

[Virus deposit information form](#)

The NCPV brochure is coming soon!
Follow us on Twitter @NCPV for news of its issue.

Middle East Respiratory Syndrome (MERS)


MERS is an emerging respiratory disease caused by a novel coronavirus (MERS-CoV). More than 1700 cases of MERS-CoV infection, including 628 deaths, have been reported to the World Health Organization (WHO) since September 2012, the majority from the Kingdom of Saudi Arabia (88%).

Epidemiological data suggests that infection in many of the primary cases followed close contact with dromedary camels. There have also been sporadic hospital outbreaks including one involving 186 cases in the Republic of Korea in 2015.

PHE has developed an algorithm on the public health investigation and management of possible cases of MERS-CoV but many aspects of this infection remain unresolved. More research is required and NCPV support this by making an authenticated strain of MERS-CoV available to the wider scientific community.

MERS-CoV: public health investigation and management of possible cases

NCPV MERS strain



[Read the algorithm](#)



Centre for Virus Research collaboration

NCPV seeks to develop external collaborations with the best research institutes in the world; with this in mind, a team from NCPV visited the University of Glasgow Centre for Virus Research (CVR) in December 2016. Julie Russell, Head of PHE Culture Collections said, "We were received very warmly by Professor Massimo Palmarini. He and his team are at the cutting edge of international virology research and I was delighted that we had such a useful discussion". The purpose of the meeting was to extend the collaborations already in place between CVR and PHE's National Infection Service (NIS) to include adding more important authenticated viruses to NCPV.

NCPV's unique expertise lies in our global dispatch of authenticated viruses which requires very specialist knowledge of biosecurity, biological safety, export and legal requirements. NCPV is also fortunate in being able to rely on expertise from NIS Reference, Research and High Containment Microbiology laboratories.

Events

NCPV will be attending the following events between January and April 2017. We hope to see you there:

Frontiers in Laboratory Medicine (FiLM) - Exhibition area

31 January - 1 February, Austin Court, Birmingham, UK

The Microbiology Society Annual Conference 2017 - Stand 6

3 - 6 April, Edinburgh International Conference Centre (EICC), Edinburgh, UK

27th ECCMID 2017 - Stand 34A

22 - 25 April, Vienna, Austria

NCPV is a dynamic collection of viruses.

Keep up to date with our new strains!



www.phe-culturecollections.org.uk/signup



www.phe-culturecollections.org.uk